Retatrutide Comparisons
How does retatrutide compare to tirzepatide, semaglutide, and the next generation of obesity drugs? These pages examine mechanism, efficacy, safety, and regulatory status — with evidence ratings and primary source citations.
No head-to-head trial data exists between retatrutide and other approved agents. All comparisons draw on separate trial populations and should be interpreted accordingly.
Comparison Pages
Each page provides a structured, evidence-rated analysis. Comparisons are based on published trial data, not marketing claims.
Retatrutide vs Tirzepatide
Triple agonist vs dual agonist
Tirzepatide (Mounjaro/Zepbound) activates GLP-1 and GIP receptors. Retatrutide adds glucagon receptor agonism. This page compares mechanism, Phase 2/3 weight-loss data, cardiovascular endpoints, and safety profiles across 10 evidence-rated dimensions.
Retatrutide vs Semaglutide
Triple agonist vs single GLP-1 agonist
Semaglutide (Ozempic/Wegovy) is a single GLP-1 receptor agonist. Retatrutide targets three receptors simultaneously. This comparison covers mechanism depth, weight-loss magnitude, MASH/CKD data, and what the additional receptor targets add — and risk.
Retatrutide vs Next-Generation Obesity Drugs
Orforglipron, mazdutide, CagriSema, and beyond
The obesity drug pipeline extends well beyond retatrutide. This page compares retatrutide against oral GLP-1 agents (orforglipron), amylin/GLP-1 combinations (CagriSema), and other triple agonists in development — with evidence levels for each comparison.
Is Retatrutide a GLP-1 or GLP-3?
Clearing up the most common misnomer
Retatrutide is frequently mislabeled as a "GLP-3" drug online. This page explains why that label is pharmacologically incorrect, what receptors retatrutide actually targets, and why the distinction matters for understanding its mechanism and comparing it to other agents.
Next-Generation Drugs, Switching, and Dosing
How These Comparisons Are Made
All efficacy and safety data is drawn from peer-reviewed publications, ClinicalTrials.gov records, and official Eli Lilly announcements — not secondary summaries or press coverage.
Retatrutide has not been tested against tirzepatide or semaglutide in a randomized controlled trial. Comparisons reflect separate trial populations with different designs, durations, and inclusion criteria.
Each claim carries an evidence level (A–E) based on study design, sample size, and publication status. Preliminary or company-reported data is labeled as such.
Retatrutide is investigational. It is not FDA approved. This status is stated clearly on every comparison page and is not softened or implied to be otherwise.
Interested in Retatrutide?
Retatrutide is not yet FDA approved. If you want a physician to review your eligibility for investigational access or clinical trial enrollment, start a physician review.
Start Physician Review